LysRs-IN-2 是一种赖氨酸 tRNA 合成酶(KRS)抑制剂,其对恶性疟原虫 KRS (PfKRS) 和小隐孢子虫 KRS (CpKRS) 的IC50值分别为 0.015 μM、0.13 μM。
生物活性 | LysRs-IN-2 is alysyl-tRNA synthetase (KRS)inhibitor withIC50s of 0.015 μM and 0.13 μM forPlasmodiumfalciparumlysyl-tRNA synthetase (PfKRS) andCryptosporidium parvumlysyl-tRNA synthetase (CpKRS), respectively[1]. |
IC50& Target | IC50: 0.015 μM (PfKRS), 0.13 μM (CpKRS)[1] |
体外研究 (In Vitro) | LysRs-IN-2 is active against whole-cell bloodstreamP. falciparum3D7 (EC50=0.27 μM),HsKRS (IC50=1.8 μM), HepG2 cells (EC50=49 μM), andCryptosporidium parvum(EC50=2.5 μM)[1].
|
体内研究 (In Vivo) | LysRs-IN-2 (1.5 mg/kg; orally once a day for 4 days) reduces parasitemia by 90% in the murineP. falciparumSCID model. LysRs-IN-2 (20 mg/kg; orally once a day for 7 days) reduces parasite shedding in NOD SCID gamma mice and INF-γ-knockout mice (Cryptosporidiummouse models)[1].
Animal Model: | MurineP. falciparumNODscidIL2Rγnull (SCID) model[1] | Dosage: | 1.5 mg/kg | Administration: | Orally once a day for 4 days | Result: | Reduced parasitemia by 90% in the malaria SCID mouse model. |
Animal Model: | NOD SCID gamma and INF-γ–knockout mouse models (Cryptosporidiummouse models)[1] | Dosage: | 20 mg/kg | Administration: | Orally once a day for 7 days | Result: | Reduced parasite shedding below detection level, and this reduction was sustained for 3 wk after treatment had stopped in INF-γ-knockout mice.
Dosed orally at a concentration of 20 mg/kg once a day for 7 days showed 96% reduction of parasite shedding comparable to paromomycin in NOD SCID gamma mice. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
溶解性数据 | In Vitro: DMSO : ≥ 60 mg/mL(168.87 mM) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 2.8144 mL | 14.0722 mL | 28.1444 mL | 5 mM | 0.5629 mL | 2.8144 mL | 5.6289 mL | 10 mM | 0.2814 mL | 1.4072 mL | 2.8144 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (stored under nitrogen)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (5.85 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.85 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 1.5 mg/mL (4.22 mM); Clear solution
此方案可获得 ≥ 1.5 mg/mL (4.22 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 15.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 1.5 mg/mL (4.22 mM); Clear solution
此方案可获得 ≥ 1.5 mg/mL (4.22 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 15.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|